{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:08:27Z","timestamp":1765004907329,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hemophilia A (HA) is an X-linked recessive bleeding disorder characterized by qualitative and quantitative deficiency of factor VIII (FVIII). The development of inhibitor antibodies against FVIII is the most challenging complication of treatment. Mutations in the FVIII gene is one of the genetic factors that leads to development of FVIII inhibitors especially intron 22 inversion (Inv22).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study was carried out to assess the frequency of Inv22 of FVIII gene in Egyptian patients with hemophilia A and its role as a risk factor for developing inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Seventy-two patients with severe HA and 48 patients with moderate HA were enrolled in the current study. All patients were treated on demand with either plasma-derived factor VIII or recombinant factor VIII concentrates. Genotyping of FVIII Inv22 was performed by LD-PCR while the presence and magnitude of inhibitor activity in blood was determined by the Bethesda assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Around 23% of all hemophilia cases had positive Inv22. Intron 22 inversion mutation was detected in 6 and 33% of patients with moderate and severe HA respectively. Twenty-one cases (18%) of all hemophilic patients developed inhibitors. Thirty-7% of patients with Inv22 had inhibitor in their blood, almost all, but one, had severe HA. The risk of an inhibitor development during replacement therapy was four folds higher among Inv22 positive cases as compared with mutation negative peers (OR 4.3, 95% CI 1.6\u201311.9,<jats:italic>P<\/jats:italic>\u00a0=\u20090.003).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The prevalence of Inv22 of F VIII in Egyptian hemophiliacs is nearly like that of other population. This mutation was more frequently detected among severe hemophilic patients as compared with moderately affected peers. The presence of Inv22 mutation significantly predispose to FVIII inhibitor development.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13052-020-00878-5","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T10:02:59Z","timestamp":1600077779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?"],"prefix":"10.1186","volume":"46","author":[{"given":"Laila M.","family":"Sherief","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama A.","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala Mosaad","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan S.","family":"Sherbiny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesam a","family":"Mokhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa A. A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8535-3838","authenticated-orcid":false,"given":"Naglaa M.","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehia H.","family":"Abdel Maksoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"issue":"9371","key":"878_CR1","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","volume":"361","author":"PHB Bolton-Maggs","year":"2003","unstructured":"Bolton-Maggs PHB, Pasi KJ. Haemophilias a and b. Lancet. 2003;361(9371):1801\u20139.","journal-title":"Lancet."},{"issue":"12","key":"878_CR2","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/bies.10360","volume":"25","author":"HMH Spronk","year":"2003","unstructured":"Spronk HMH, Govers-Riemslag JWP, ten Cate H. The blood coagulation system as a molecular machine. Bioessays. 2003;25(12):1220\u20138.","journal-title":"Bioessays"},{"issue":"5992","key":"878_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/312326a0","volume":"312","author":"J Gitschier","year":"1984","unstructured":"Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, et al. Characterization of the human factor VIII gene. Nature. 1984;312(5992):326.","journal-title":"Nature."},{"issue":"1","key":"878_CR4","first-page":"66","volume":"51","author":"D Freije","year":"1992","unstructured":"Freije D, Schlessinger D. A 1.6-Mb contig of yeast artificial chromosomes around the human factor VIII gene reveals three regions homologous to probes for the DXS115 locus and two for the DXYS64 locus. Am J Hum Genet. 1992;51(1):66.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"878_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/0049-3848(91)90652-D","volume":"61","author":"S Cinotti","year":"1991","unstructured":"Cinotti S, Longo G, Messori A, Morfini M, Blomback M, Schimpf K, et al. Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study. Thromb Res. 1991;61(4):385\u201393.","journal-title":"Thromb Res"},{"issue":"10 Suppl","key":"878_CR6","first-page":"7","volume":"85","author":"J Oldenburg","year":"2000","unstructured":"Oldenburg J, Brackmann H-H, Schwaab R. Risk factors for inhibitor development in hemophilia a. Haematologica. 2000;85(10 Suppl):7\u201313.","journal-title":"Haematologica."},{"key":"878_CR7","first-page":"82","volume-title":"Seminars in hematology. Elsevier","author":"J Oldenburg","year":"2004","unstructured":"Oldenburg J, Schr\u00f6der J, Brackmann HH, M\u00fcller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. In: Seminars in hematology. Elsevier; 2004. p. 82\u20138."},{"key":"878_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1351-8216.2001.00134.x","volume":"8","author":"J Oldenburg","year":"2002","unstructured":"Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia. 2002;8:23\u20139.","journal-title":"Haemophilia."},{"issue":"2","key":"878_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/hae.12302","volume":"20","author":"JM Soucie","year":"2014","unstructured":"Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, et al. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 2014;20(2):230\u20137.","journal-title":"Haemophilia."},{"issue":"Suppl 1","key":"878_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/bloodadvances.2018GS112562","volume":"2","author":"A Jandial","year":"2018","unstructured":"Jandial A, Mishra K, Sandal R, Jindal N, Goni D, Lad D, et al. Hemophilia in the developing world: transforming lives through international collaboration. Blood Adv. 2018;2(Suppl 1):39.","journal-title":"Blood Adv"},{"issue":"03","key":"878_CR11","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1055\/s-0037-1615621","volume":"85","author":"GCII White","year":"2001","unstructured":"White GCII, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Thromb Haemost. 2001;85(03):560.","journal-title":"Thromb Haemost"},{"issue":"6","key":"878_CR12","first-page":"190","volume":"3","author":"W Iqbal","year":"2013","unstructured":"Iqbal W, Raza M, Khan MS. Intron 22 inversions in severe hemophiliacs. Am J Med. 2013;3(6):190\u20136.","journal-title":"Am J Med"},{"issue":"4","key":"878_CR13","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood.V92.4.1458","volume":"92","author":"Q Liu","year":"1998","unstructured":"Liu Q, Nozari G, Sommer SS. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia a. Blood. 1998;92(4):1458\u20139.","journal-title":"Blood."},{"issue":"3","key":"878_CR14","first-page":"346","volume":"4","author":"MS Khan","year":"2015","unstructured":"Khan MS, Rizwan M, Ghani R, Ahmad S, Jameel N. Prevalence of intron 22 inversions in Pakistani hemophilic patients. Int J Med Heal Sci. 2015;4(3):346\u201350.","journal-title":"Int J Med Heal Sci"},{"issue":"5","key":"878_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3324\/haematol.12427","volume":"93","author":"M Margaglione","year":"2008","unstructured":"Margaglione M, Castaman G, Morfini M, Rocino A, Santagostino E, Tagariello G, et al. The Italian AICE-genetics hemophilia a database: results and correlation with clinical phenotype. Haematologica. 2008;93(5):722\u20138.","journal-title":"Haematologica."},{"issue":"4","key":"878_CR16","first-page":"352","volume":"53","author":"J Sawecka","year":"2005","unstructured":"Sawecka J, Skulimowska J, Windyga J, \u0141opaciuk S, Ko\u015bcielak J. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in polish patients with severe hemophilia a. Arch Immunol Ther Exp. 2005;53(4):352\u20136.","journal-title":"Arch Immunol Ther Exp"},{"key":"878_CR17","doi-asserted-by":"crossref","unstructured":"Luna-za H, Mantilla-capacho JM, Beltra CP, Esparza-flores A, Lo B, Aguilar-lo L. Frequency of Intron 1 and 22 Inversions of Factor VIII Gene in Mexican Patients With Severe Hemophilia A. Am J Hematol. 2007, 287;(October 2006):283\u20137.","DOI":"10.1002\/ajh.20865"},{"issue":"6","key":"878_CR18","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1182\/blood.V86.6.2206.bloodjournal8662206","volume":"86","author":"SE Antonarakis","year":"1995","unstructured":"Antonarakis SE, Rossiter JP, Young M, Horst J, De Moerloose P, Sommer SS, et al. Factor VIII gene inversions in severe hemophilia a: results of an international consortium study. Blood. 1995;86(6):2206\u201312.","journal-title":"Blood."},{"issue":"6","key":"878_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/1076029611435094","volume":"18","author":"NJ Faridi","year":"2012","unstructured":"Faridi NJ, Kumar P, Husain N. Prevalence of intron 1 inversion of cases with hemophilia a in north Indian population. Clin Appl Thromb. 2012;18(6):599\u2013603.","journal-title":"Clin Appl Thromb"},{"issue":"1","key":"878_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood.V99.1.168","volume":"99","author":"RD Bagnall","year":"2002","unstructured":"Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia a. Blood. 2002;99(1):168\u201374.","journal-title":"Blood."},{"issue":"6","key":"878_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/MBC.0b013e328329e456","volume":"20","author":"TM Owaidah","year":"2009","unstructured":"Owaidah TM, Alkhail HA, Al Zahrani H, Al Musa A, Al Saleh M, Riash MA, et al. Molecular genotyping of hemophilia a in Saudi Arabia: report of 2 novel mutations. Blood Coagul Fibrinolysis. 2009;20(6):415\u20138.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"878_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1365-2516.2009.02081.x","volume":"16","author":"A Awidi","year":"2010","unstructured":"Awidi A, Ramahi M, Alhattab D, Mefleh R, Dweiri M, Bsoul N, et al. Study of mutations in Jordanian patients with haemophilia a: identification of five novel mutations. Haemophilia. 2010;16(1):136\u201342.","journal-title":"Haemophilia."},{"issue":"22","key":"878_CR23","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.1007\/s00216-014-7969-3","volume":"406","author":"T-Y Pan","year":"2014","unstructured":"Pan T-Y, Wang C-C, Shih C-J, Wu H-F, Chiou S-S, Wu S-M. Genotyping of intron 22 inversion of factor VIII gene for diagnosis of hemophilia a by inverse-shifting polymerase chain reaction and capillary electrophoresis. Anal Bioanal Chem. 2014;406(22):5447\u201354.","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"878_CR24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2516.2009.02180.x","volume":"16","author":"Y CHEN","year":"2010","unstructured":"CHEN Y, S HU, S CHENG, T CHAO. Genetic analysis of haemophilia a in Taiwan. Haemophilia. 2010;16(3):538\u201344.","journal-title":"Haemophilia."},{"issue":"7","key":"878_CR25","first-page":"778","volume":"88","author":"H Andrikovics","year":"2003","unstructured":"Andrikovics H, Klein I, Bors A, Nemes L, Marosi A, V\u00e1radi A, et al. Analysis of large structural changes of the factor VIII gene, involving intron 1 and 22, in severe hemophilia a. Haematologica. 2003;88(7):778\u201384.","journal-title":"Haematologica."},{"issue":"1","key":"878_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-2350-9-53","volume":"9","author":"SY Lin","year":"2008","unstructured":"Lin SY, Su YN, Hung CC, Tsay W, Chiou SS, Chang CT, Ho HN, Lee CN. Mutation spectrum of 122 hemophilia a families from Taiwanese population by LD-PCR, DHPLC, multiplex PCR and evaluating the clinical application of HRM. BMC Med Genet. 2008 Dec 1;9(1):53.","journal-title":"BMC Med Genet"},{"issue":"11","key":"878_CR27","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","volume":"7","author":"A Coppola","year":"2009","unstructured":"Coppola A, Margaglione M, Santagostino E, Rocino A, Grandone E, Mannucci PM, et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia a patients with high-responding inhibitors. J Thromb Haemost. 2009;7(11):1809\u201315.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"878_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1365-2516.2001.00505.x","volume":"7","author":"K Ghosh","year":"2001","unstructured":"Ghosh K, Shetty S, Kulkarni B, Nair S, Pawar A, Khare A, et al. Development of inhibitors in patients with haemophilia from India. Haemophilia. 2001;7(3):273\u20138.","journal-title":"Haemophilia."},{"issue":"3","key":"878_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1365-2516.1999.00300.x","volume":"5","author":"I Scharrer","year":"1999","unstructured":"Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia a patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemoph Off J World Fed Hemoph. 1999;5(3):145\u201354.","journal-title":"Haemoph Off J World Fed Hemoph"},{"issue":"06","key":"878_CR30","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1055\/s-0038-1649954","volume":"74","author":"R Schwaab","year":"1995","unstructured":"Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, et al. Haemophilia a: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74(06):1402\u20136.","journal-title":"Thromb Haemost"},{"key":"878_CR31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0609.1979.tb02856.x","volume":"23","author":"ESG Antibody","year":"1979","unstructured":"Antibody ESG. Of FV. Development of factor VIII antibody in haemophilic monozygotic twins. Scand J Haematol. 1979;23:64\u20138.","journal-title":"Scand J Haematol"},{"issue":"12","key":"878_CR32","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","volume":"119","author":"SC Gouw","year":"2012","unstructured":"Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, Margaglione M, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia a: systematic review and meta-analysis. Blood. 2012;119(12):2922\u201334.","journal-title":"Blood."},{"key":"878_CR33","first-page":"2","volume":"19","author":"K-JR Inhibitors","year":"2013","unstructured":"Inhibitors K-JR. Our greatest challenge. Can we minimize the incidence? Haemophilia. 2013;19:2\u20137.","journal-title":"Haemophilia."},{"issue":"6","key":"878_CR34","first-page":"EREP04","volume":"88","author":"W Kreuz","year":"2003","unstructured":"Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, et al. Epidemiology of inhibitors and current treatment strategies. Haematologica. 2003;88(6):EREP04.","journal-title":"Haematologica"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-020-00878-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-020-00878-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-020-00878-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T19:21:44Z","timestamp":1723576904000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-020-00878-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1186\/s13052-020-00878-5","relation":{},"ISSN":["1824-7288"],"issn-type":[{"type":"electronic","value":"1824-7288"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the research and ethical committee of the participating hospitals. All parents of enrolled children signed written informed consents for participation of their children in the current study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All parents of enrolled children signed written informed consents for publication the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests related to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}